ES2250434T3 - Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores. - Google Patents

Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores.

Info

Publication number
ES2250434T3
ES2250434T3 ES01952097T ES01952097T ES2250434T3 ES 2250434 T3 ES2250434 T3 ES 2250434T3 ES 01952097 T ES01952097 T ES 01952097T ES 01952097 T ES01952097 T ES 01952097T ES 2250434 T3 ES2250434 T3 ES 2250434T3
Authority
ES
Spain
Prior art keywords
cyclopamine
cells
ccb
medicament
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01952097T
Other languages
English (en)
Spanish (es)
Inventor
Sinan Tas Dr.
Oktay Avci Dr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2250434(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2250434T3 publication Critical patent/ES2250434T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES01952097T 2001-07-02 2001-07-02 Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores. Expired - Lifetime ES2250434T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
ES2250434T3 true ES2250434T3 (es) 2006-04-16

Family

ID=21619326

Family Applications (3)

Application Number Title Priority Date Filing Date
ES01952097T Expired - Lifetime ES2250434T3 (es) 2001-07-02 2001-07-02 Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores.
ES10163813.8T Expired - Lifetime ES2534400T3 (es) 2001-07-02 2001-07-02 Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
ES02736467T Expired - Lifetime ES2246011T3 (es) 2001-07-02 2002-04-19 Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10163813.8T Expired - Lifetime ES2534400T3 (es) 2001-07-02 2001-07-02 Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
ES02736467T Expired - Lifetime ES2246011T3 (es) 2001-07-02 2002-04-19 Utilizacion de ciclopamina para la preparacion de un medicamento para el tratamiento de la psoriaris.

Country Status (14)

Country Link
EP (4) EP1561464A3 (https=)
JP (3) JP2004536045A (https=)
KR (1) KR20090125833A (https=)
CN (2) CN1525859B (https=)
AT (2) ATE305300T1 (https=)
AU (1) AU2001272892B8 (https=)
BR (1) BR0117063A (https=)
CA (1) CA2452151C (https=)
DE (2) DE60113733T2 (https=)
DK (2) DK1401438T3 (https=)
ES (3) ES2250434T3 (https=)
PT (1) PT1411938E (https=)
RU (1) RU2312661C2 (https=)
WO (2) WO2002078703A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1411938B1 (en) 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
CA2619889C (en) * 2005-08-22 2020-05-05 The Johns Hopkins University Use of itraconazole and salts thereof for treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
AU2007329678A1 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
RU2009137012A (ru) 2007-03-07 2011-04-20 Инфинити Дискавери, Инк. (Us) Аналоги циклопаминлактама и способы их применения
JP2010520295A (ja) * 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
US20240384291A1 (en) 2021-09-13 2024-11-21 Sinan Tas Effective Interventions With Aging and Diseases Of Aging Of Human and Their Consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
DK1115398T3 (da) * 1998-09-23 2010-08-16 Res Dev Foundation Tocopheroler, tocotrienoler, andre chroman- og sidekædederivater og anvendelser deraf
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ATE283700T1 (de) * 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1235851B1 (en) * 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis

Also Published As

Publication number Publication date
BR0117063A (pt) 2004-07-27
DE60204966D1 (de) 2005-08-11
DK1411938T3 (da) 2005-11-07
CA2452151C (en) 2012-01-03
EP2216022A1 (en) 2010-08-11
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
JP5424923B2 (ja) 2014-02-26
ATE305300T1 (de) 2005-10-15
WO2002078704A1 (en) 2002-10-10
RU2004103074A (ru) 2005-05-10
RU2312661C2 (ru) 2007-12-20
KR20090125833A (ko) 2009-12-07
JP2004536045A (ja) 2004-12-02
CA2452151A1 (en) 2002-10-10
DE60204966T2 (de) 2006-05-18
EP2216022B1 (en) 2015-01-07
JP2010132691A (ja) 2010-06-17
DE60113733D1 (de) 2006-02-09
CN1230169C (zh) 2005-12-07
EP1561464A2 (en) 2005-08-10
CN1525859B (zh) 2010-05-05
CN1525859A (zh) 2004-09-01
DE60113733T2 (de) 2006-06-29
EP1401438A1 (en) 2004-03-31
EP2862570A1 (en) 2015-04-22
CN1522146A (zh) 2004-08-18
JP2014028834A (ja) 2014-02-13
EP1561464A3 (en) 2007-04-25
WO2002078703A8 (en) 2003-06-12
EP1401438B1 (en) 2005-09-28
PT1411938E (pt) 2005-11-30
WO2002078703A1 (en) 2002-10-10
ATE299022T1 (de) 2005-07-15
DK1401438T3 (da) 2006-02-13
ES2246011T3 (es) 2006-02-01
AU2001272892B8 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
ES2250434T3 (es) Utilizacion de ciclopamina en el tratamiento del carcinoma de celulas basales y de otros tumores.
US20110104254A1 (en) Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells
AU2001272892A1 (en) Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
ES2245465T3 (es) Dioles de compuestos de norborneno y norbornano para el tratamiento de trastornos de la pigmentacion, enfermedades neurodegenerativas o enfermedades proliferativas de la piel.
ES2207252T3 (es) Uso de piperina y sus derivados para tratar trastornos de pigmentacion de la piel y cancer de piel.
CN105687185B (zh) 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法
Huang et al. Anticancer effects of gossypetin from Hibiscus sabdariffa in oral squamous cell carcinoma
US20150073008A1 (en) Topical Application of Vinca Alkaloids for the Treatment of Actinic Keratosis
Cho et al. Photochemical reaction to increase melanogenesis using Buddleja officinalis and blue light-emitting diode irradiation in B16F10
RU2565535C2 (ru) Пептидная защита против токсического воздействия ультрафиолетового излучения
Cham Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large and troublesome skin cancers
ZA200305432B (en) Treatment of skin disorders.
KR20160085581A (ko) 에보디아민을 유효성분으로 포함하는 피부노화 예방 또는 치료용 조성물
ES2214066T3 (es) Preparacion de khellina para la terapia topica de la psoriasis, sus subtipos, formas especiales, asi como la terapia topica de eczemas.
RU2308948C2 (ru) Применение циклопамина для лечения базально-клеточной эпителиомы (карциномы) и других опухолей
CN121015680B (zh) 野黄芩苷与红景天苷联合在治疗日光性皮炎中的应用
CN120154719A (zh) Bcl2抑制剂在治疗先天性巨大黑痣中的应用
US20120258937A1 (en) Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis
CN121422169A (zh) 莪术乙醇提取物及其制备方法和在抗脑转移瘤中的应用
KR20250108066A (ko) 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途
HK1174565B (en) Method of treating scars and ss-catenin-mediated disorders using nefopam compounds